Videos

see all
  • Automatic recurring contributions : the best way to save 1:41
  • Driving our economy with the Fonds de solidarité FTQ 90 sec.
  • The First Edition of the RDV Relève inc. (in French only) 2:49

Press releases

June 22, 2015

Gladius Pharmaceuticals raises CAD $4.1 million to battle multi-drug-resistant infections

Gladius Pharmaceuticals Inc., a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections, announced today the closing of a $4.1 million Series A financing. The round was led by Lumira Capital Investment Management via its Merck Lumira Biosciences Funds, with participation from Québec’s Fonds de solidarité FTQ and SR One which participated with funds from the GlaxoSmithKline (GSK) Canada Life Sciences Innovation Fund

Created in 1983, the Fonds de solidarité FTQ is a development capital fund that calls upon the solidarity and savings of Quebecers to help fulfill its mission to contribute to Québec's economic growth by creating and protecting jobs through investments primarily in small and medium-sized businesses in all spheres of activity.

The Fonds also seeks to encourage Quebecers to save for retirement and to offer its over half a million shareholders-savers a reasonable return over and above the outstanding tax benefits they receive for purchasing Fonds shares. A leading purveyor of unsecured risk capital (growth and venture capital), the Fonds continues to drive our economy.